Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22798981 | 1.00 | KMT2A (0.47) | KMT2AMEN1PKMTSHRADRA1B | |
| SCHEMBL22042597 | 1.00 | KMT2A (0.47) | KMT2AMEN1PKMTSHRADRA1B | |
| SCHEMBL22799085 | 1.00 | KMT2A (0.47) | KMT2AMEN1PKMTSHRADRA1B | |
| SCHEMBL22042609 | 1.00 | KMT2A (0.47) | KMT2AMEN1PKMTSHRADRA1B | |
| SCHEMBL22799156 | 1.00 | KMT2A (0.47) | KMT2AMEN1PKMTSHRADRA1B | |
| SCHEMBL4397528 | 0.98 | KMT2A (0.49) | KMT2AMEN1PKMTSHRADRA1B | |
| SCHEMBL10981771 | 0.94 | ADRA1B (0.43) | KMT2AMEN1PKMTSHRADRA1B | |
| SCHEMBL8071932 | 0.94 | ADRA1B (0.43) | KMT2AMEN1PKMTSHRADRA1B | |
| SCHEMBL8538168 | 0.92 | KMT2A (0.44) | KMT2AMEN1PKMTSHRADRA1B | |
| SCHEMBL312170 | 0.92 | KMT2A (0.50) | KMT2AMEN1PKMTSHRADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032568-A1 | POLYALKYLENE GLYCOL-CONTAINING COMPOUND | NIPPON SHOKUBAI CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| EP-3753968-A1 | POLYALKYLENE GLYCOL-CONTAINING COMPOUND | Nippon Shokubai Co., Ltd. (JP) | 2020-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032568-A1 | POLYALKYLENE GLYCOL-CONTAINING COMPOUND | AQP1, MGLL, SGMS1 | KMT2A 2733/4885MEN1 3052/4885PKM 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.